Price Chart

DATE TIME TYPE PERIOD REPORTED
EPS
ESTIMATED
EPS
SURPRISE
11/03/2022* -- Results Q3 2022 -- 0.28 --
11/03/2022* 17:00 EST Earnings Call Q3 2022 -- -- --
08/03/2022 -- Results Q2 2022 0.24 0.28 -15.29%
08/03/2022 17:00 EST Earnings Call Q2 2022 -- -- --
05/05/2022 -- Results Q1 2022 0.20 0.31 -35.48%
05/05/2022 17:00 EST Earnings Call Q1 2022 -- -- --
02/15/2022 -- Results Q4 2021 0.35 0.35 0.00%
02/15/2022 17:00 EST Earnings Call Q4 2021 -- -- --
*Estimated Date/Time

Earnings

Next Report Date 11/03/2022 (est.)
EPS Estimate Upgrade
Last Actual EPS Upgrade

Loading chart...
Last Report Date 08/03/2022
Beat/Miss Upgrade
Return Since -1.04%
Last FQE 06/30/2022
Next FQE 09/30/2022

Profile

Edit
Corcept Therapeutics Inc is a commercial-stage pharmaceutical company engaged in the discovery and development of medications that treat severe metabolic, oncologic and neuropsychiatric disorders by modulating the effect of the hormone cortisol.
URL https://www.corcept.com
Investor Relations URL https://ir.corcept.com/investor-relations
HQ State/Province California
Sector Healthcare
Industry Biotechnology
Equity Style Small Cap/Value
Next Earnings Release Nov. 03, 2022 (est.)
Last Earnings Release Aug. 03, 2022
Next Ex-Dividend Date N/A
Last Ex-Dividend Date N/A

Dividends

Dividend Per Share (TTM) --
2017
2018
2019
2020
2021
No data available
 
6.00%
4.00%
2.00%
 
Yield to Market 0.00
Yield to Sector 0.00
Yield to Industry 0.00
Last Dividend Amt. --
Dividend Frequency --
Last Ex-Dividend Date --
Yield (TTM) 0.00%
Forward Yield --
Payout Ratio 0.00%
Cash Payout Ratio 0.00%
Consistent Payer (5Y) No
Consistent Growth (5Y) No

Ownership

Insider Ownership Percentage Upgrade
Jul '20
Nov '20
Mar '21
 
80.00%
40.00%
10.00%
 

Short Interest

Short Interest Upgrade
Percent of Shares Outstanding Short Upgrade
Jul '20
Nov '20
Mar '21
 
80.00%
40.00%
10.00%
 

Total Returns Comparison

Edit comparables

Annual Total Returns Versus Peers

Edit comparables
Loading chart...
Name
2015
2016
2017
2018
2019
2020
2021
YTD
66.00%
45.78%
148.8%
-26.02%
-9.43%
116.2%
-24.31%
43.48%
1.38%
11.96%
21.83%
-4.38%
31.49%
18.40%
28.71%
-9.34%
--
--
--
47.37%
-28.28%
-41.24%
147.1%
-62.00%
-13.79%
-67.42%
0.22%
-78.75%
511.8%
31.15%
540.8%
-53.27%
32.33%
-32.38%
2.42%
-0.65%
0.53%
28.66%
30.72%
-0.44%
-24.68%
-61.02%
76.34%
-50.00%
170.7%
368.6%
-63.48%
-56.26%
As of August 12, 2022.

Profile

Edit
Corcept Therapeutics Inc is a commercial-stage pharmaceutical company engaged in the discovery and development of medications that treat severe metabolic, oncologic and neuropsychiatric disorders by modulating the effect of the hormone cortisol.
URL https://www.corcept.com
Investor Relations URL https://ir.corcept.com/investor-relations
HQ State/Province California
Sector Healthcare
Industry Biotechnology
Equity Style Small Cap/Value
Next Earnings Release Nov. 03, 2022 (est.)
Last Earnings Release Aug. 03, 2022
Next Ex-Dividend Date N/A
Last Ex-Dividend Date N/A

Ownership

Insider Ownership Percentage Upgrade
Jul '20
Nov '20
Mar '21
 
80.00%
40.00%
10.00%
 

Short Interest

Short Interest Upgrade
Percent of Shares Outstanding Short Upgrade
Jul '20
Nov '20
Mar '21
 
80.00%
40.00%
10.00%
 

Top Fund Holders

Symbol Dollars Invested % Weight
FEWXVX 659013.0 USD 6.59%
PJP 15.24M USD 4.52%
XPH 9.619M USD 4.04%
PTH 6.619M USD 2.49%
JSML 2.249M USD 2.48%
KAUBX 121.28M USD 2.40%
PSCH 8.441M USD 2.32%
WSCIX 492341.0 USD 2.13%
PSLBX 3.324M USD 1.21%
HIL269 4.918M USD 1.18%
IHE 4.497M USD 1.02%
RBF199 438829.0 USD 0.68%

Top Portfolio Holders

0 of 0

Other Resources

Whale Wisdom 13F Filings
Seeking Alpha Call Transcripts
Morningstar Insider Trading
Nasdaq Institutional Ownership
Nasdaq Option Chain
SEC SEC Filings
Twitter CORT Tweets